Objective: To analyze the effects of chemotherapy on peripheral blood DC cells and related immune cytokines (NKG2D, DC cells, TNF-a, IFN-r, HMGB-1) in patients with non-small cell lung cancer (NSCLC). Methods: Ninety-five NSCLC patients who attended the Oncology Department of the Affiliated Hospital of Chengde Medical College from September 2018 to February 2021 were selected as the research objects, and the changes in the expression levels of DC cells, NKG2D, TNF-a, IFN-r, HMGB-1 in the peripheral blood of patients at different time points (before chemotherapy, after the first chemotherapy, and after the second chemotherapy) were analyzed, and the correlation between DC cells in blood and NKG2D, TNF-a, IFN-r, HMGB-1 at each time point was explored. Results: The expression levels of NKG2D, TNF-a, IFN-r, and HMGB-1 in the peripheral blood of the patient before chemotherapy, after the first chemotherapy, and after the second chemotherapy gradually decreased, and there was no significant change in DC cells, except for DC cells at different times. The difference between each factor of each point was statistically significant (all P < 0.05). Pearson correlation analysis showed that there was no correlation between peripheral blood DC cells of patients at different time points and other factors. Conclusion: The decrease of other immune cytokines except DC cells in peripheral blood of patients with NSCLC after chemotherapy may be one of the mechanisms by which the patient’s immune function is suppressed. There is no correlation between DC cells and other factors.
References
[1]
Fu, Y., Huang, L., Tang, H., et al. (2020) Hsa Circ RNA012515 Is Highly Expressed in NSCLC Patients and Affects Its Prognosis. Cancer Management and Research, 12, 1877. https://doi.org/10.2147/CMAR.S245525
[2]
Thunnissen, E., de Langen, A.J. and Smit, E.F. (2017) PD-L1 IHC in NSCLC with a Global and Methodological Perspective. Lung Cancer, 113, 102-105. https://doi.org/10.1016/j.lungcan.2017.09.010
[3]
Tsoulos, N., Papadopoulou, E., Metaxa-Mariatou, V., et al. (2017) Tumor Molecular Profiling of NSCLC Patients Using Next Generation Sequencing. Oncology Reports, 38, 3419-3429. https://doi.org/10.3892/or.2017.6051
[4]
Leonetti, A., Facchinetti, F., Rossi, G., et al. (2018) BRAF in Non-Small Cell Lung Cancer (NSCLC): Pickaxing Another Brick in the Wall. Cancer Treatment Reviews, 66, 82-94. https://doi.org/10.1016/j.ctrv.2018.04.006
[5]
Leone, R.D. and Emens, L.A. (2018) Targeting Adenosine for Cancer Immunotherapy. Journal for Immunotherapy of Cancer, 6, 57. https://doi.org/10.1186/s40425-018-0360-8
[6]
Riley, R.S., June, C.H., Langer, R., et al. (2019) Delivery Technologies for Cancer Immunotherapy. Nature Reviews Drug Discovery, 18, 175-196. https://doi.org/10.1038/s41573-018-0006-z
[7]
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science, 359, 1350-1355. https://doi.org/10.1126/science.aar4060
[8]
Nam, J., Son, S., Park, K.S., et al. (2019) Cancer Nanomedicine for Combination Cancer Immunotherapy. Nature Reviews Materials, 4, 398-414. https://doi.org/10.1038/s41578-019-0108-1
[9]
Sahin, U. and Türeci, Ö. (2018) Personalized Vaccines for Cancer Immunotherapy. Science, 359, 1355-1360. https://doi.org/10.1126/science.aar7112
[10]
Hegde, P.S. and Chen, D.S. (2020) Top 10 Challenges in Cancer Immunotherapy. Immunity, 52, 17-35. https://doi.org/10.1016/j.immuni.2019.12.011
[11]
Goldberg, M.S. (2019) Improving Cancer Immunotherapy through Nanotechnology. Nature Reviews Cancer, 19, 587-602. https://doi.org/10.1038/s41568-019-0186-9
[12]
Ma, Y., Ren, Y., Dai, Z.J., et al. (2017) IL-6, IL-8 and TNF-α Levels Correlate with Disease Stage in Breast Cancer Patients. Advances in Clinical and Experimental Medicine, 26, 421-426. https://doi.org/10.17219/acem/62120
[13]
Akdis, M., Aab, A., Altunbulakli, C., et al. (2016) Interleukins (from IL-1 to IL-38), Interferons, Transforming Growth Factor β, and TNF-α: Receptors, Functions, and Roles in Diseases. Journal of Allergy and Clinical Immunology, 138, 984-1010. https://doi.org/10.1016/j.jaci.2016.06.033
[14]
Mitoma, H., Horiuchi, T., Tsukamoto, H., et al. (2018) Molecular Mechanisms of Action of Anti-TNF-α Agents-Comparison among Therapeutic TNF-α Antagonists. Cytokine, 101, 56-63. https://doi.org/10.1016/j.cyto.2016.08.014
[15]
Hamilton, R.E., Vikram, S. and Farraye, F.A. (2018) Systemic TNF-α Reduction by Blocking IgE-Mediated Cellular Activation in Inflammatory Bowel Disease. Cancer Immunology Research, 2, 1-8. https://doi.org/10.33425/2639-8494.1019
[16]
Andersson, U., Yang, H. and Harris, H. (2018) Extracellular HMGB1 as a Therapeutic Target in Inflammatory Diseases. Expert Opinion on Therapeutic Targets, 22, 263-277. https://doi.org/10.1080/14728222.2018.1439924
[17]
Ayers, M., Lunceford, J., Nebozhyn, M., et al. (2017) IFN-γ-Related mRNA Profile Predicts Clinical Response to PD-1 Blockade. The Journal of Clinical Investigation, 127, 2930-2940. https://doi.org/10.1172/JCI91190
Mojic, M., Takeda, K. and Hayakawa, Y. (2018) The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. International Journal of Molecular Sciences, 19, 89. https://doi.org/10.3390/ijms19010089
[20]
Dhar, P. and Wu, J.D. (2018) NKG2D and Its Ligands in Cancer. Current Opinion in Immunology, 51, 55-61. https://doi.org/10.1016/j.coi.2018.02.004
[21]
Zingoni, A., Molfetta, R., Fionda, C., et al. (2018) NKG2D and Its Ligands: “One for All, All for One”. Frontiers in Immunology, 9, 476. https://doi.org/10.3389/fimmu.2018.00476
[22]
Sayed, M.A., Ahmed, M., Elsheikh, M.G., et al. (2016) PWM Control Techniques for Single-Phase Multilevel Inverter Based Controlled DC Cells. Journal of Power Electronics, 16, 498-511. https://doi.org/10.6113/JPE.2016.16.2.498
[23]
Yang, G., Jiang, Y., Tong, P., et al. (2017) Alleviation of Enterotoxigenic Escherichia coli Challenge by Recombinant Lactobacillus plantarum Expressing a FaeG- and DC-Targeting Peptide Fusion Protein. Beneficial Microbes, 8, 379-391. https://doi.org/10.3920/BM2016.0116
